ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside

$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside

A surge of low-priced names is capturing trader attention as December 2025 opens, with several companies showing fresh catalysts, rising volume, or renewed investor interest. From biotech breakthroughs to entertainment-sector momentum, these $1 stocks are positioning themselves as year-end watchlist leaders.

Jasper Therapeutics Inc. (NASDAQ: JSPR) is one of December’s most active micro-cap biotechs after releasing encouraging preliminary data from its ETESIAN Study in allergic asthma. A single dose of briquilimab showed reductions in sputum eosinophils and improved lung function at 6 and 12 weeks. The company also completed its BEACON Study investigation, concluding that past variability stemmed from patient-selection issues, not the drug itself. Together, these updates have reignited investor interest and firmly positioned JSPR on this month’s high-watch list.

Fitell Corporation (NASDAQ: FTEL) is drawing heavy attention after reporting solid fiscal-year revenue growth and improved profitability while also approving a $3 million share-repurchase program. The company continues to expand its health and robotics initiatives through its 2F Robotics venture, backed by stablecoin-linked funding.

Kartoon Studios Inc. (NYSE: TOON) is emerging as one of the strongest sub-$1 entertainment stocks heading into year-end, posting double-digit revenue growth led by Mainframe Studios and a record October for Kartoon Channel!. The company strengthened its balance sheet with recent financing and is advancing major initiatives, including its new “STAN A.I.” animation technology. With rising operational momentum across multiple business lines, TOON is becoming a standout among December’s low-priced stocks giants in the industry Warner Bros. Discovery (NASDAQ: WBD) and Paramount Skydance Corporation (NASDAQ: PSKY)

My Size, Inc. (NASDAQ: MYSZ) Trading quietly around the $1 mark, My Size has not issued major new developments early this month. The stock often exhibits sharp low-float fluctuations on even modest retail interest, making it a name that traders monitor closely despite the absence of near-term catalysts.

Power Metallic Mines (TSX-V: PNPN | OTCQB: PNPNF) reported one of its strongest drilling results to date, intercepting 4.40 meters of 12.18% Cu (14.34% CuEq) within a broader 20.40-meter interval grading 2.91% Cu (3.58% CuEq) at its Lion Zone during the summer drill program. The company also completed the extension of hole PN-24-064 to better define a large off-hole BHEM anomaly, reinforcing the potential scale of the system. Read Entire Release.

Peraso Inc. (NASDAQ: PRSO) continues hovering just under the dollar level as the market awaits its next mmWave or fixed-wireless update. Earlier in the year, the company secured multiple design wins and new OEM volume orders—momentum that traders still view as potentially reactivating. While December has been quiet so far, PRSO remains capable of rapid price movement given its history and lean float.

Beyond Meat, Inc. (NASDAQ: BYND) remains in the mid-$1 range as the company continues navigating competitive pressures, rising production costs, and shifting consumer sentiment in the plant-based sector. Despite the absence of major new catalysts, BYND consistently attracts interest due to its recognizable brand and potential for sizable percentage swings at low share prices.

Aprea Therapeutics Inc. (NASDAQ: APRE) trades just above $1 as it continues pushing forward its precision-oncology programs targeting DNA-damage repair, p53 modulation, and other genetically driven cancer pathways. Although December has not brought new clinical updates, APRE remains on watch for biotech momentum traders looking for asymmetry within early-stage oncology development.

December Micro-Cap Setup: Momentum Rotates Back to the $1 Tier

With volatility returning and traders seeking year-end catalysts, the $1-stock category is once again in focus. This month’s lineup offers a clear division:

  • JSPR leading with clinical data momentum
  • FTEL gaining traction on revenue strength and share-repurchases
  • TOON standing out on operational growth and digital-media expansion
  • BYND maintaining brand-driven speculative interest
  • PNPN.V PRSO, APRE, PNPNF and MYSZ offering potential on any fresh news trigger

As December continues, these names may deliver high-velocity moves driven by news flow, sentiment, or sector rotation.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.38
-2.04 (-0.87%)
AAPL  284.15
-2.04 (-0.71%)
AMD  217.60
+2.36 (1.10%)
BAC  54.09
+0.90 (1.69%)
GOOG  320.62
+4.60 (1.46%)
META  639.60
-7.50 (-1.16%)
MSFT  477.73
-12.27 (-2.50%)
NVDA  179.59
-1.87 (-1.03%)
ORCL  207.73
+6.63 (3.30%)
TSLA  446.74
+17.50 (4.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.